Headache is an adverse event associated with the use of proton pump inhibitors (PPIs). Recently, migraine has emerged more specifically as a potential adverse event with PPI use. The objectives of this work were to capitalize on existing data to evaluate the association between migraine and severe headache prevalence and use of acid-suppression therapy, including… Continue reading Use of #Acid-Suppression Therapy and Odds of #Migraine and Severe Headache in the National Health and Nutrition Examination Survey
Tag: PPI
#Proton pump inhibitors and #dementia: A nationwide population-based study
Proton pump inhibitors (PPIs) may increase dementia risk. However, it is currently unknown whether timing of exposure or age at dementia diagnosis influence the risk.METHODSWe assessed associations between cumulative PPI use and dementia at different ages in a nationwide Danish cohort of 1,983,785 individuals aged 60 to 75 years between 2000 and 2018.RESULTSDuring follow-up, there… Continue reading #Proton pump inhibitors and #dementia: A nationwide population-based study
Cumulative Use of #Proton Pump Inhibitors and Risk of #Dementia: The Atherosclerosis Risk in Communities Study
Studies on the association between proton pump inhibitor (PPI) use and dementia report mixed results and do not examine the impact of cumulative PPI use. We evaluated the associations between current and cumulative PPI use and risk of incident dementia in the Atherosclerosis Risk in Communities (ARIC) Study.Methods. These analyses used participants from a community-based cohort… Continue reading Cumulative Use of #Proton Pump Inhibitors and Risk of #Dementia: The Atherosclerosis Risk in Communities Study
Proton Pump Inhibitor Use and Risks of Cardiovascular Disease and Mortality in Patients With Type 2 Diabetes
Proton pump inhibitors (PPIs) are widely used drugs for gastric acid–related diseases and may affect the gut microbiome.ObjectiveWe aimed to evaluate the associations of PPI use with risks of cardiovascular disease (CVD) and all-cause mortality in patients with type 2 diabetes (T2D).MethodsWe analyzed the associations of PPI use with risks of coronary artery disease (CAD),… Continue reading Proton Pump Inhibitor Use and Risks of Cardiovascular Disease and Mortality in Patients With Type 2 Diabetes
#Proton pump inhibitors and risk of #colorectal cancer
To determine whether proton pump inhibitors (PPIs) are associated with an increased risk of colorectal cancer, compared with histamine-2 receptor antagonists (H2RAs). Design The United Kingdom Clinical Practice Research Datalink was used to identify initiators of PPIs and H2RA from 1990 to 2018, with follow-up until 2019. Cox proportional hazards models were fit to estimate… Continue reading #Proton pump inhibitors and risk of #colorectal cancer
Use of #proton pump inhibitors to treat persistent #throat symptoms: multicentre, double blind, randomised, placebo controlled trial
To assess the use of proton pump inhibitors (PPIs) to treat persistent throat symptoms.. ..Random blinded allocation (1:1) to either 30 mg lansoprazole twice daily or matched placebo twice daily for 16 weeks. Main outcome measures Primary outcome was symptomatic response at 16 weeks measured using the total reflux symptom index (RSI) score. Secondary outcomes… Continue reading Use of #proton pump inhibitors to treat persistent #throat symptoms: multicentre, double blind, randomised, placebo controlled trial
The influence of #proton pump inhibitor therapy on the outcome of #infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies
In treating patients with inflammatory bowel disease (IBD), how concomitant medications influence the response to infliximab is largely unexplored. We aim to evaluate whether proton pump inhibitors (PPIs) affect the response to infliximab therapy in patients with IBD.. Among the five randomised controlled studies, there were 889 and 147 patients on infliximab with and without… Continue reading The influence of #proton pump inhibitor therapy on the outcome of #infliximab therapy in inflammatory bowel disease: a patient-level meta-analysis of randomised controlled studies
Efficacy and safety of gastrointestinal #bleeding prophylaxis in critically #ill patients: an updated systematic review and network meta-analysis of randomized trials
Motivated by a new randomized trial (the PEPTIC trial) that raised the issue of an increase in mortality with proton pump inhibitors (PPIs) relative to histamine-2 receptor antagonists (H2RAs), we updated our prior systematic review and network meta-analysis (NMA) addressing the impact of pharmacological gastrointestinal bleeding prophylaxis in critically ill patients. Seventy-four trials enrolling 39… Continue reading Efficacy and safety of gastrointestinal #bleeding prophylaxis in critically #ill patients: an updated systematic review and network meta-analysis of randomized trials
Association Between Acute #Gastroenteritis and Continuous Use of Proton Pump Inhibitors During Winter Periods of Highest Circulation of Enteric Viruses
An increased risk of acute bacterial enteric infections has been reported among patients receiving proton pump inhibitor (#PPI) therapy. The risk of acute gastroenteritis (AGE) of viral origin associated with continuous PPI exposure has been less studied ..At least 1 AGE epidemic episode was identified in 3131 patients (1.3%) receiving PPI therapy and in 4327… Continue reading Association Between Acute #Gastroenteritis and Continuous Use of Proton Pump Inhibitors During Winter Periods of Highest Circulation of Enteric Viruses
2 Medical News 